Biogen stock plummets 28% after company halts Alzheimer’s trials

Shares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an investigational drug designed to treat symptoms of early Alzheimer’s disease.

from MarketWatch.com - Top Stories https://ift.tt/2FntfHR
via IFTTT

Kommentare

Beliebte Posts aus diesem Blog

Kelley Blue Book: What is the Mercedes-Benz EQB?

This is the German automaker's all-electric version of the popular compact GLB SUV. from MarketWatch.com - Top Stories https://ift.tt/3zuLGnP via IFTTT

Tax Loophole Found for Home-Equity Loan Interest

Homeowners may still qualify for a tax break on their home-equity loan interest thanks to a loophole in the recent Tax Cuts and Jobs Act. from rss_headline https://ift.tt/2SZ3e6R via IFTTT

MarketWatch First Take: Big Tech painted as the railroad barons of the digital age in antitrust hearing

For the most part — if you could tune out the political grandstanding that had nothing to do with antirust — the Congressional hearing on Big Tech gave many pointed examples of how four of the biggest tech companies in the U.S. abuse their dominant power and thwart competition. from MarketWatch.com - Top Stories https://ift.tt/2XbPKcx via IFTTT

Finance

Dieses Blog durchsuchen